Safety of terlipressin for injection based on electronic medical records

doi:10.19803/j.1672-8629.2022.06.15

Abstract

Abstract: Objective To investigate the incidence of adverse drug reactions (ADR) and clinical symptoms related to terlipressin. Methods The electronic medical records and ADR reports of patients using terlipressin in the Affiliated Hospital of Guizhou Medical University between 2016 to 2019 were collected. Statistical analysis was conducted according to patients' gender, age, clinical manifestations and outcomes. Results A total of 1 816 medical records and 56 ADR reports of patients using terlipressin were collected. The incidence of ADR was 3.08%, and higher among females than among males. Males over 45 years old were the most vulnerable. Adverse reactions mainly involved the digestive system and cardiovascular system, manifested as diarrhea, abdominal pain and palpitations. Conclusion The clinical manifestations of terlipressin-induced adverse drug reactions vary. To prevent serious ADR and ensure drug safety, clinicians should be vigilant and drug monitoring needs to be strengthened.

Key words: terlipressin, adverse drug reactions, safety analysis, rational drug use

CLC Number:

R994.11

LI Xiaofei, CHENG Rong, WU Xuemei, LIU Zhi. Safety of terlipressin for injection based on electronic medical records[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 654-656.

References

[1] GARCIA-TSAO G, SANYAL AJ, GRACE ND, et al.Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis[J]. Hepatology, 2007, 46(3): 922-938
[2] WANG DY.Srudy on definition and scope of adverse drug reaction surveillance[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(12): 732-738.
[3] TIEU C, BREDER CD.A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries[J]. Drug Saf, 2018, 41(12): 1375-1385.
[4] CHENG JJ, WANG Z.Grading criteria for severity of adverse drug reaction damage and its bibliometric analysis[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2019, 19(4): 487-490.
[5] LI J, DU H.Epidemiological analysis of patients with liver disease admitted in infectious diseases department of Tangdu Hospital from 2013 to 2019[J]. Clinical Research and Practice(临床医学研究与实践), 2020, 5(10): 1-2, 5.
[6] MOKDAD AA, LOPEZ AD, SHAHRAZ S, et al.Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis[J]. BMC Med, 2014, 12: 145.
[7] NEVENS F, BITTENCOURT PL, COENRAAD MJ, et al.Recomm-endations on the diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with cirrhosis[J]. Dig Dis Sci, 2019, 64(6): 1419-1431.
[8] KRAG A, BORUP T, MØLLER S, et al. Efficacy and safety of terlipr-essin in cirrhotic patients with variceal bleeding or hepatorenal syndrome[J]. Adv Ther, 2008, 25(11): 1105-1140.
[9] CAVALLIN M, PIANO S, ROMANO A, et al.Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study[J]. Hepatology, 2016, 63(3): 983-992.
[10] GERBES AL, HUBER E, GÜLBERG V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration[J]. Gastroenterology, 2009, 137(3): 1179.
[11] CAVALLIN M, FASOLATO S, MARENCO S, et al.The treatment of hepatorenal syndrome[J]. Dig Dis, 2015, 33(4): 548-554.
[12] GLUUD LL, CHRISTENSEN K, CHRISTENSEN E, et al. Terlipr-essin for hepatorenal syndrome[J]. Cochrane Database Syst Rev, 2012(9): CD005162.
[13] OZEL COSKUN BD, KARAMAN A, GORKEM H, et al.Terlipressin-induced ischemic skin necrosis: a rare association[J]. Am J Case Rep, 2014, 15: 476-479
[14] KIM HR, LEE YS, YIM HJ, et al.Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome[J]. Clin Mol Hepatol, 2013, 19(4): 417-420.
[15] ŠÍMA M, POKORNÝ M, PAĎOUR F, et al. Terlipressin induced severe hyponatremia[J]. Prague Med Rep, 2016,117(1): 68-72.